Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: A placebo-controlled multicenter study

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1077-1084

  Simons, J P ^a   Aaronson, N K ^a   Vansteenkiste, J F ^a   ten Velde, G P ^a   Muller, M J ^a   Drenth, B M ^a   Erdkamp, F L ^a   Cobben, E G ^a   Schoon, E J ^a   Smeets, J B ^a   Schouten, H C ^a   Demedts, M ^a   Hillen, H F ^a   Blijham, G H ^a   Wouters, E F ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYPROHEPTADINE; GESTAGEN; HYDRAZINE SULFATE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ANOREXIA; APPETITE; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HEADACHE; HEART FAILURE; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 9244223548     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1077     Document Type: Article

References (26)

1. Theologides A: Cancer cachexia. Cancer 43:2004-2012, 1979
2. Shils ME: Principles of nutritional therapy. Cancer 43:2093-2102, 1979
3. Tisdale MJ: Cancer cachexia. Anticancer Drugs 4:115-125, 1993
4. Inagaki J, Rodriguez V, Bodey GP: Causes of death in cancer patients. Cancer 33:568-573, 1974
5. DeWys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491-497, 1980
6. Holmes S, Dickerson JWT: Malignant disease: Nutritional implications of disease and treatment. Cancer Metastasis Rev 6:357-381, 1987
7. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607-1609, 1974
8. Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 69:751-754, 1985
9. Kardinal CG, Loprinzi CL, Schaid DJ, et al: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657-2662, 1990
10. Chlebowski RT, Bulcavage L, Grosvenor M, et al: Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 8:9-15, 1990
11. Cavalli F, Goldhirsch A, Jungi F, et al: Randomized trial of low- versus high-dose medroxyprogesterone acetate in the treatment of postmenopausal patients with advanced breast cancer, in Pellegrini A, Robustelli Della Cuna G (eds): Role of Medroxyprogesterone in Endocrine-Related Tumors, vol 3. New York, NY, Raven, 1984, pp 79-89
12. Tchekmedyian NS, Tait N, Moody M, et al: High-dose megestrol acetate: A possible treatment for cachexia. JAMA 257:1195-1198, 1987
13. Bruera E, Macmillan K, Kuehn N, et al: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66:1279-1282, 1990
14. Loprinzi CL, Ellison NM, Schaid DJ, et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127-1132, 1990
15. Tchekmedyian NS, Hickman M, Siau J, et al: Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268-1274, 1992
16. Feliu J, Gonzalez-Baron M, Berrocal A, et al: Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 15:436-440, 1992
17. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
18. Bjordal K, Kaasa S, Mastekaasa A: Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 28:847-856, 1994
19. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
20. Niezgoda HE, Pater JL: A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 2:319-325, 1993
21. Aaronson NK, Cull A, Kaasa S, et al: The European Organisation for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology: An update, in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials (ed 2) New York, NY, Raven, 1996, pp 179-189
22. Metropolitan Life Insurance Company: New weight standards for men and women. Stat Bull Metrop Life Found 64:1-4, 1983
23. Löwik MRH, Westenbrink S, Meulmeester JF, et al: Onderzoek naar de voeding en voedingstoestand van zelfstandig wonende mensen van 65 tot 80 jaar. Voeding 48:177-191, 1987
24. Cohen J (ed): Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, Erlbaum, 1988
25. Schmoll E, Wilke H, Thole R, et al: Megestrol acetate in cancer cachexia. Semin Oncol 18:32-34, 1991 (suppl 2)
26. Downer S, Joel A, Allbright H, et al: A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67:1102-1105, 1993